Holifya, a female-led Italian startup based in Milan, has raised €2 million in a fundraising round led by CDP Venture Capital's Nex... fund to expand its AI-powered GLP-1 obesity clinic. ^[1] Holifya, a digital clinic in Italy focused on pharmacologic obesity treatment, raised €2 million in a funding round consisting of €1.6 million in equity and €0.4 million in debt capital and grants. ^[2] The proportion of eligible Italians who use GLP-1 drugs is less than 1%, whereas in the UK it is over 4%. ^[3] Adoption of GLP-1 therapy in Italy remains low at less than 1% of eligible patients, compared to 2% in Germany and over 4% in the UK. ^[4] Holifya's AI system integrates up to 3,000 biomarkers per patient, including genetic, blood chemistry, and anamnestic data, combined with behavioral and clinical information to personalize therapy. ^[5] Over 23 million adults in Italy are overweight or obese, with approximately 11 million eligible for GLP-1 therapy, representing one of the largest pools in Europe. ^[6] Holifya's AI-powered platform is designed to optimize patient care and drug management for obesity treatment. ^[7] The startup aims to scale its operations to increase access to GLP-1 drugs in Italy. ^[8]